IP Library Granted Patent US 9,532,826
Granted Patent B2
US 9,532,826 · App. 14/159,758 · Granted Jan 3, 2017

System and method for sinus surgery

Inventor: Joe D. Sartor (Longmont, CO)
Assignee: COVIDIEN LP
A61B18/042A61B2017/00323A61B2018/00327
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,532,826
App. No.
14/159,758
Granted
Jan 3, 2017
Kind
B2
Abstract

A method for treating a sinus cavity is provided. The method includes the steps of inserting a plasma applicator into a sinus cavity defined in a bone mass, positioning the plasma applicator adjacent a tissue formation, generating a selectively reactive plasma effluent at the plasma applicator and directing the selectively reactive plasma effluent at the tissue formation. The selective nature of the reactive plasma enables treatment of specific targets inside the sinus while minimizing the effect on other tissues. Such treatment includes, but not limited to, sterilization of bacterial colonies, vaporization of unwanted tissues or foreign masses, stimulation of tissues by enriching the content of reactive oxygen and nitrous oxide pathways, and combinations thereof.

Claims (18)

1. A method for treating a sinus cavity, the method comprising the steps of:

inserting a plasma applicator into a sinus cavity defined in a bone mass;

positioning the plasma applicator adjacent a tissue formation;

generating a selectively reactive plasma effluent at the plasma applicator; and

directing the selectively reactive plasma effluent at the tissue formation,

wherein the selectively reactive plasma effluent selectively removes the tissue formation without perforating bone.

2. A method according to claim 1 , wherein the positioning step further includes the step of:

deflecting a distal portion of the plasma applicator to direct the distal portion toward the tissue formation.

3. A method according to claim 1 , wherein the generating step further includes the steps of:

supplying ionizable media and at least one precursor feedstock to the plasma applicator; and

igniting the ionizable media and the at least one precursor feedstock at the plasma applicator to form the selectively reactive plasma effluent.

4. A method according to claim 3 , wherein the generating step further includes the step of:

selecting the at least one precursor feedstock to have a higher chemical reactivity with the tissue formation than with the bone mass of the sinus cavity.

5. A method according to claim 3 , wherein the at least one precursor feedstock is selected from the group consisting of hydrogen peroxide, water, oxygen and nitrogen.

6. A method according to claim 3 , wherein the ionizable media is selected from the group consisting of argon and helium.

7. A method according to claim 3 , further comprising the step of applying at least one hemostatic agent to the tissue formation.

8. A method according to claim 3 , wherein the at least one precursor feedstock comprises at least one hemostatic agent.

9. A method according to claim 1 , wherein the plasma effluent has a maximum temperature of about 60° C.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2014
From: SARTOR, JOE D.
To: COVIDIEN LP
Reel/Frame 032008/0850 →
Continuity (2)
Provisional Application 61773609 · Mar 6, 2013
Related Publication 20140257276A1 · Sep 11, 2014